| Print
Editas Medicine (EDIT)
Common SharesThis share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP
Company profile
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary ene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.
Address
11 Hurley Street
Cambridge
MA
USA
02141
Telephone
+1 617 4019083
Forecast key dates
| Name | Key Date |
|---|---|
| Editas Medicine Inc Fourth Quarter Earnings Results for 2026 | 2027-03-09T00:00:00 |
| Editas Medicine Inc Annual Report for 2026 | 2027-03-09T00:00:00 |
| Editas Medicine Inc Third Quarter Earnings Results for 2026 | 2026-11-10T00:00:00 |
| Editas Medicine Inc Second Quarter Earnings Results for 2026 | 2026-08-12T00:00:00 |
| Editas Medicine Inc Annual General Meeting for 2026 | 2026-05-29T08:30:00 |
| Editas Medicine Inc First Quarter Earnings Results for 2026 | 2026-05-12T00:00:00 |
| Editas Medicine Inc First Quarter Earnings Conference Call for 2026 | 2026-05-12T00:00:00 |
Previous key dates
| Name | Key Date |
|---|---|
| Barclays 28th Annual Global Healthcare Conference | 2026-03-12T08:00:00 |
| Editas Medicine Inc Fourth Quarter Earnings Results for 2025 | 2026-03-09T00:00:00 |
| Editas Medicine Inc Annual Report for 2025 | 2026-03-09T00:00:00 |
| TD Cowen 46th Annual Health Care Conference | 2026-03-02T10:30:00 |
| 8th Annual Evercore Healthcare Conference | 2025-12-02T09:10:00 |
| Editas Medicine Inc Third Quarter Earnings Results for 2025 | 2025-11-10T00:00:00 |
| Chardan 9th Annual Genetic Medicines Conference | 2025-10-21T08:45:00 |
| H.C. Wainwright Genetic Medicines Virtual Conference | 2025-10-14T07:00:00 |
| Cantor Global Healthcare Conference | 2025-09-04T11:30:00 |
| Editas Medicine Lead In Vivo Development Candidate Webinar | 2025-09-02T08:00:00 |
| Editas Medicine Inc Second Quarter Earnings Results for 2025 | 2025-08-12T00:00:00 |
| Editas Medicine Inc Annual General Meeting for 2025 | 2025-05-29T08:30:00 |
| Editas Medicine Inc First Quarter Earnings Results for 2025 | 2025-05-12T00:00:00 |
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2026 AJ Bell. All rights reserved.